Showing 411-420 of 5061 results for "".
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (
- FDA Warns that Biotin May Interfere with Lab Test Resultshttps://practicaldermatology.com/news/fda-warns-that-biotin-may-interfere-with-lab-test-results/2457961/Biotin may significantly interfere with certain lab tests and cause "clinically significant incorrect lab test results," the US Food and Drug Administration warns. At least 1 death has been related to biotin interference with laboratory results, FDA officials wrote in a Saf
- Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis/2458046/New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 mo
- DermTech Secures Billing Codes for its Proprietary Melanoma Testhttps://practicaldermatology.com/news/dermtech-secures-billing-codes-for-its-proprietary-melanoma-test/2458115/The American Medical Association (AMA) has granted DermTech, Inc. Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAM
- Study: Soolantra is Both Anti-Inflammatory and Anti-Demodexhttps://practicaldermatology.com/news/study-soolantra-is-both-anti-inflammatory-and-anti-demodex/2458132/A recently published study sought to find scientific rationale for the dual anti-inflammatory and anti-parasitic mode of action of topical ivermectin 1% cream (Soolantra) in patients with rosacea. In a monocentric pilot study, 20 Caucasian patients with moderate to severe rosacea, as asse